Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Fineline Cube Mar 31, 2026
Company Deals

Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors

Fineline Cube Mar 31, 2026
Company Deals

Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs

Fineline Cube Mar 31, 2026
Company Deals

Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership

Fineline Cube Mar 31, 2026
Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Fineline Cube Mar 31, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Abbisko Therapeutics Secures FDA Clearance for ABSK061 Pediatric Achondroplasia Trial, Advancing Oral FGFR2/3 Inhibitor

Fineline Cube Mar 31, 2026
Company Drug

ImmuneOnco Doses First Patient in Phase III Trial of World’s First CD47/CD20 Bispecific for Follicular Lymphoma

Fineline Cube Mar 31, 2026
Company

Sanofi Reports 9.9% Sales Growth to EUR 43.6B, Driven by Dupixent and China

Fineline Cube Jan 30, 2026

Sanofi (NASDAQ: SNY) reported full‑year 2025 revenues of EUR 43.626 billion (USD 47.8 billion), representing 9.9% growth at constant exchange...

Company

Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China

Fineline Cube Jan 30, 2026

Roche (SWX: ROG, OTCMKTS: RHHBY) reported full‑year 2025 sales of CHF 61.5 billion : (USD 69.1 billion), representing 7% growth at...

Company Drug

United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial

Fineline Cube Jan 29, 2026

United Laboratories International Holdings Ltd (HKG: 3933) announced that the U.S. Food and Drug Administration (FDA)...

Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a licensing agreement with ApolloBio Corp.,...

Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026

Chengdu Kanghua Biological Products Co., Ltd. (SHE: 300841) announced a plan to increase capital investment...

Company Deals

Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered

Fineline Cube Jan 29, 2026

Lisata Therapeutics announced the termination of its licensing agreement with Qilu Pharmaceutical Co., Ltd. for...

Company Deals

WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases

Fineline Cube Jan 29, 2026

WuXi Biologics (HKG: 2269) announced a collaboration agreement with Guizhou Sinorda Biomedicineic Co., Ltd. to provide...

Company Deals

NeuShen Therapeutics Raises Series A+ for CNS Drug Development

Fineline Cube Jan 29, 2026

NeuShen Therapeutics, a Sino‑US biotech focused on central nervous system (CNS) disorders, announced the completion...

Company Deals

Organon Completes $465M JADA System Sale to Laborie Medical

Fineline Cube Jan 29, 2026

Organon (NYSE: OGN) announced the completed acquisition of its JADA system by Laborie Medical Technologies Corp....

Company Drug

MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study

Fineline Cube Jan 29, 2026

MicuRx Pharmaceuticals Inc., (SHA: 688373) a Sino‑US biopharmaceutical company, announced it has received approval from...

Company Drug

Huiyu Pharma HYP-6589 Gets NMPA Nod for NSCLC Osimertinib Combo

Fineline Cube Jan 29, 2026

Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced that the National Medical Products Administration (NMPA)...

Company

Servier Oncology Revenue Drives 16% Growth, US Sales Surge 70%

Fineline Cube Jan 29, 2026

Servier announced a 16.2% year‑on‑year (YOY) revenue increase to EUR 6.9 billion (USD 7.52 billion) for the 2024/25 financial...

Company Drug

Changchun High‑Tech’s Firsekibart Filing Accepted for Non‑Infectious Uveitis

Fineline Cube Jan 29, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical Products...

Company

Danaher Q4 Revenue Grows 3% to $24.6B on Biotech and Diagnostics Innovation

Fineline Cube Jan 29, 2026

Danaher Corporation (NYSE: DHR) reported fourth‑quarter and full‑year 2025 earnings with global revenues rising 3% year‑on‑year...

Company Deals Hospital

Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing

Fineline Cube Jan 29, 2026

Distinct Healthcare Holdings Limited, a China‑based private healthcare service provider, released its prospectus this week...

Company

Merck Establishes Chongqing China Branch in Milestone Expansion

Fineline Cube Jan 29, 2026

Merck Sharp & Dohme (MSD, NYSE: MRK), a US‑based biopharmaceutical giant, announced the establishment of a...

Company Deals

Biogen’s Litifilimab Secures FDA Breakthrough Therapy Designation for Lupus

Fineline Cube Jan 29, 2026

Biogen Inc. (NASDAQ: BIIB) announced that its investigational litifilimab has received Breakthrough Therapy Designation (BTD) from...

Company Deals

Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal

Fineline Cube Jan 29, 2026

Seamless Therapeutics, a Germany‑based gene editing company, announced a global strategic research collaboration and license...

Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Fineline Cube Jan 28, 2026

Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 1 drug TQA3605 has met the primary...

Company Drug

J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen

Fineline Cube Jan 28, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) approved...

Posts pagination

1 … 28 29 30 … 644

Recent updates

  • Amoy Diagnostics and HutchMed Secure World’s First NMPA Approval for MET Amplification Companion Diagnostic
  • Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care
  • Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors
  • Boston Scientific Secures FDA 510(k) Clearance for Asurys Fluid Management System in Kidney Stone Procedures
  • Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Amoy Diagnostics and HutchMed Secure World’s First NMPA Approval for MET Amplification Companion Diagnostic

Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Company Deals

Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors

Company Medical Device

Boston Scientific Secures FDA 510(k) Clearance for Asurys Fluid Management System in Kidney Stone Procedures

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.